The government “will push the vaccine contracts of Pfizer, Modena and Janssen for January next year” (general)

Entry 2020.12.18 12:28

The government announced that it will conclude individual negotiations with foreign pharmaceutical companies that are developing vaccines for the new coronavirus infection (Corona 19) in January next year.

Im In-taek, Head of the Health Industry Policy Office of the Ministry of Health and Welfare, at the briefing on the status of response of Crown 19 and the safety of vaccines for development abroad, Held at the Seoul Government Complex on the morning of the 18th, “Jansen and Pfizer will sign contracts in December and Moderna in January. It is,” he said.

Director Lim repeatedly emphasized on the day that “the 44 million people mentioned above by the government is the amount that can be insured before the end of next year.” Prior to this, the government announced the installation of Kobax (Installation of COVAX, World Association for the Joint Procurement of Vaccines) Through 10 million people and 34 million people through overseas vaccine development companies.

Among them, the government has already signed a contract with AstraZeneca and plans to conclude a vaccine supply contract with the three remaining global pharmaceutical companies (Pfizer, Modena and Janssen) next month.

The vaccine will be introduced in stages starting in the first quarter of next year. Director Lim said: “We are negotiating the rapid introduction of 10 million COVAX among the 44 million corona vaccines that it was decided to introduce abroad.” “He said.

They were saved from the specific time of supply for the remaining 34 million people. Director Lim said: “It is difficult to disclose the specific delivery schedule and schedule according to companies’ non-disclosure requests due to competition to secure vaccines between countries and fairness between countries according to delivery schedule.” Also, we plan to divide the quantity by quarts and bring it sequentially. “The introduction schedule is decided taking into account the inoculation plan and schedule taking into account the short shelf life and difficult storage conditions.

On the fact that the introduction of the vaccine was delayed compared to other countries, he said: “We are in the process of negotiating the purchase under high uncertainty, such as the inevitable pre-purchase of a vaccine that has not been proven to be effective or safe.” . Considering the cessation of clinical trials due to such circumstances, negotiations proceeded with public health as the top priority ”. He said: “Even after the contract, we will continue our efforts to speed up the supply period as much as possible.”

It also made the point that AstraZeneca was the only vaccine that was actually insured. Director Lim In-taek said, “AstraZeneca was the most advanced in vaccine development among several companies,” he said. Director Lim said: “We have also signed purchase agreements and supply confirmations with other companies. This is a procedure in the process of signing a contract and has the same effect as the contract.”

The government is currently in consultation with further development companies to secure additional supplies of vaccines. Director Lim said: “We are currently in consultation with further development companies such as NovaVax” and “will announce this as soon as the consultation is completed.”

Reporter Kim Yeon-ji [email protected]

Copyright © IT Chosun.